Evolus, Inc. – NASDAQ:EOLS

Evolus stock price today

$7.1
-3.99
-35.98%
Financial Health
0
1
2
3
4
5
6
7
8
9

Evolus stock price monthly change

-5.78%
month

Evolus stock price quarterly change

-5.78%
quarter

Evolus stock price yearly change

+9.26%
year

Evolus key metrics

Market Cap
694.00M
Enterprise value
20.96M
P/E
-6.25
EV/Sales
0.14
EV/EBITDA
-0.34
Price/Sales
N/A
Price/Book
0.02
PEG ratio
0.15
EPS
-1.05
Revenue
219.00M
EBITDA
-37.75M
Income
-60.00M
Revenue Q/Q
42.21%
Revenue Y/Y
40.00%
Profit margin
-50%
Oper. margin
-38.74%
Gross margin
62.4%
EBIT margin
-38.74%
EBITDA margin
-17.24%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Evolus stock price history

Evolus stock forecast

Evolus financial statements

Evolus, Inc. (NASDAQ:EOLS): Profit margin
Jun 2023 49.34M -18.14M -36.76%
Sep 2023 49.32M -16.92M -34.31%
Dec 2023 60.99M -11.83M -19.4%
Mar 2024 59.33M -13.10M -22.09%
Evolus, Inc. (NASDAQ:EOLS): Analyst Estimates
Mar 2024 59.33M -13.10M -22.09%
Sep 2025 132.55M 1.60M 1.21%
Oct 2025 91.2M 2.41M 2.64%
Dec 2025 99.8M 8.64M 8.66%
  • Analysts Price target

  • Financials & Ratios estimates

Evolus, Inc. (NASDAQ:EOLS): Debt to assets
Jun 2023 168983000 175.94M 104.12%
Sep 2023 167971000 187.33M 111.53%
Dec 2023 188998000 209.68M 110.95%
Mar 2024 226176000 207.73M 91.85%
Evolus, Inc. (NASDAQ:EOLS): Cash Flow
Jun 2023 -13.31M -216K 23.82M
Sep 2023 -34.82M -1.26M 21.11M
Dec 2023 813K -361K 23.52M
Mar 2024 -10.61M -797K 45.66M

Evolus alternative data

Evolus, Inc. (NASDAQ:EOLS): Employee count
Aug 2023 224
Sep 2023 215
Oct 2023 215
Nov 2023 215
Dec 2023 246
Jan 2024 246
Feb 2024 246
Mar 2024 273
Apr 2024 273
May 2024 273
Jun 2024 279
Jul 2024 279

Evolus other data

13.69% -38.37%
of EOLS is owned by hedge funds
7.67M -21.57M
shares is hold by hedge funds

Evolus, Inc. (NASDAQ:EOLS): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 11931
Feb 2024 0 11348
Mar 2024 0 136077
May 2024 0 60276
Jun 2024 0 478932
Aug 2024 0 5631
Sep 2024 0 3276
Dec 2024 0 14340
Transaction Date Insider Security Shares Price per share Total value Source
Sale
AVELAR RUI officer: See Remarks
Common Stock 2,252 $10.85 $24,439
Sale
BEAVER SANDRA officer: Chief Financial Officer
Common Stock 1,586 $10.85 $17,211
Sale
MOATAZEDI DAVID director, officer.. Common Stock 10,502 $10.85 $113,968
Sale
BEAVER SANDRA officer: Chief Financial Officer
Common Stock 3,276 $14.98 $49,074
Sale
YAMAGISHI-DRESSLER TOMOKO officer: Chief Marketing Officer
Common Stock 5,631 $15.85 $89,251
Option
MOATAZEDI DAVID director, officer.. Stock Option (Right to Buy) 175,940 $7.28 $1,280,843
Option
MOATAZEDI DAVID director, officer.. Common Stock 175,940 $7.28 $1,280,843
Sale
MOATAZEDI DAVID director, officer.. Common Stock 175,940 $12.59 $2,214,557
Option
MOATAZEDI DAVID director, officer.. Common Stock 155,278 $5.46 $847,818
Sale
MOATAZEDI DAVID director, officer.. Common Stock 155,278 $12.92 $2,006,502
Insider Compensation
Mr. David Moatazedi (1978) Pres, Chief Executive Officer & Director $1,250,000
Ms. Lauren P. Silvernail (1958) Chief Financial Officer & Executive Vice President of Corporation Devel. $633,180
Dr. Rui Avelar Dip.SportMed, M.D., C.CFP (1962) Chief Medical Officer and Head of R&D
$631,260
Friday, 13 December 2024
businesswire.com
Monday, 18 November 2024
zacks.com
Thursday, 14 November 2024
zacks.com
Wednesday, 6 November 2024
zacks.com
businesswire.com
Friday, 1 November 2024
businesswire.com
Thursday, 31 October 2024
businesswire.com
Wednesday, 30 October 2024
zacks.com
Friday, 11 October 2024
businesswire.com
Friday, 27 September 2024
businesswire.com
Friday, 9 August 2024
businesswire.com
Wednesday, 31 July 2024
seekingalpha.com
zacks.com
reuters.com
investors.com
Wednesday, 17 July 2024
businesswire.com
Monday, 24 June 2024
businesswire.com
Wednesday, 12 June 2024
businesswire.com
Friday, 7 June 2024
businesswire.com
Tuesday, 21 May 2024
zacks.com
Monday, 20 May 2024
businesswire.com
Wednesday, 15 May 2024
businesswire.com
Friday, 10 May 2024
businesswire.com
businesswire.com
Tuesday, 7 May 2024
Seeking Alpha
Zacks Investment Research
Friday, 3 May 2024
Zacks Investment Research
Thursday, 25 April 2024
Zacks Investment Research
Tuesday, 23 April 2024
Business Wire
Wednesday, 20 March 2024
Seeking Alpha
  • What's the price of Evolus stock today?

    One share of Evolus stock can currently be purchased for approximately $7.1.

  • When is Evolus's next earnings date?

    Unfortunately, Evolus's (EOLS) next earnings date is currently unknown.

  • Does Evolus pay dividends?

    No, Evolus does not pay dividends.

  • How much money does Evolus make?

    Evolus has a market capitalization of 694.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 35.98% to 202.09M US dollars.

  • What is Evolus's stock symbol?

    Evolus, Inc. is traded on the NASDAQ under the ticker symbol "EOLS".

  • What is Evolus's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Evolus?

    Shares of Evolus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Evolus's key executives?

    Evolus's management team includes the following people:

    • Mr. David Moatazedi Pres, Chief Executive Officer & Director(age: 47, pay: $1,250,000)
    • Ms. Lauren P. Silvernail Chief Financial Officer & Executive Vice President of Corporation Devel.(age: 67, pay: $633,180)
    • Dr. Rui Avelar Dip.SportMed, M.D., C.CFP Chief Medical Officer and Head of R&D(age: 63, pay: $631,260)
  • How many employees does Evolus have?

    As Jul 2024, Evolus employs 279 workers, which is 2% more then previous quarter.

  • When Evolus went public?

    Evolus, Inc. is publicly traded company for more then 7 years since IPO on 8 Feb 2018.

  • What is Evolus's official website?

    The official website for Evolus is evolus.com.

  • Where are Evolus's headquarters?

    Evolus is headquartered at 520 Newport Center Drive, Newport Beach, CA.

  • How can i contact Evolus?

    Evolus's mailing address is 520 Newport Center Drive, Newport Beach, CA and company can be reached via phone at +94 92844555.

Evolus company profile:

Evolus, Inc.

evolus.com
Exchange:

NASDAQ

Full time employees:

322

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

520 Newport Center Drive
Newport Beach, CA 92660

CIK: 0001570562
ISIN: US30052C1071
CUSIP: 30052C107